Kenneth J. Collins

Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO

Quark Software, Inc. develops and distributes publishing software. It offers a wide range of products from customizable solutions for large organizations in government, finance and manufacturing through brand management and design software for agencies, marketing departments and designers. The firm’s products include Quark Publishing Platform, Quark Author, Quark XML Author, QuarkCopyDesk, QuarkXPress Server, and Quark Brand Manager. The company was founded by Tim Gill and Mark Pope in 1981 and is headquartered in Denver, CO.

Evolutionary Genomics, Inc. is a holding company, which engages in the development of Adapted Traits Platform for crops production. It uses the platform to find genes responsible for increased crop yield, pest and disease resistance, salt tolerance and even sweetness. The company was founded by Walter Messier in 2000 and is headquartered in Lafayette, CO.